Proscar (finasteride) NDC 78206-153

NDC codes

FDA NDC Directory

Product NDC (as listed)78206-153Labeler and product segments. Claims need a package NDC.

Product NDC at billing width78206-0153Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
78206-153-01	78206015301	30 TABLET, FILM COATED in 1 BOTTLE (78206-153-01)Marketed from Jun 1, 2021
78206-153-02	78206015302	100 TABLET, FILM COATED in 1 BOTTLE (78206-153-02)Marketed from Jun 1, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Proscar
Generic name (nonproprietary): finasteride
Active ingredients: Finasteride — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Organon LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020180
Marketing start: Jun 1, 2021
Listing expires: Dec 31, 2027
Other FDA classes: 5-alpha Reductase Inhibitors (Mechanism)
Identifiers: Product ID 78206-153_979b0a0c-7868-4ec1-8887-f2b7e43f4326SPL ID 979b0a0c-7868-4ec1-8887-f2b7e43f4326SPL set ID 6f988153-fc74-4ca4-b29a-111f750c4a4bRxCUI 201961, 310346UNII 57GNO57U7GUPC 0378206153012
Pharmacologic class: 5-alpha Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N478206015301 followed by a unit qualifier and the quantity

Package 78206-0153-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 18, 2026.

Indications (excerpt from the label)

PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) ( 1.2 ). Limitations of Use : PROSCAR is not approved for the prevention of prostate cancer ( 1.3 ). 1.1 Monotherapy PROSCAR ® is indicated f…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)